To the full analysis
Shanghai Allist Pharmaceuticals stock: growth
688578.SSShanghai Allist Pharmaceuticals reported $777.91M in revenue for fiscal 2025, up 45.8% on the prior year, up 521.2% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
125.6%
per year from 2017 to 2025
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2017 | |
|---|---|---|
| Revenue | 521.2% | 125.6% |
| Revenue per share | 497.3% | no data |
| Earnings | no data | no data |
| Earnings per share | no data | no data |
| Free cash flow | no data | no data |
| Free cash flow per share | no data | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2017 | $1.16M | −$5.84M | $1.31M |
| 2018 | $692.83K | −$14.61M | −$19.98M |
| 2019 | $94.44K | −$59.61M | −$52.3M |
| 2020 | $84.11K | −$46.57M | −$42.77M |
| 2021 | $79.5M | $2.74M | −$24.44M |
| 2022 | $118.62M | $19.57M | −$7.83M |
| 2023 | $302.66M | $96.6M | $90.99M |
| 2024 | $533.56M | $214.43M | $194.32M |
| 2025 | $777.91M | $327.12M | $0 |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = CN¥6.6683)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 9 Oct 2026)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.